Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Astrazeneca (AZNCF) EBT Margin (2016 - 2025)

Historic EBT Margin for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to 16.96%.

  • Astrazeneca's EBT Margin rose 57700.0% to 16.96% in Q4 2025 from the same period last year, while for Dec 2025 it was 21.11%, marking a year-over-year increase of 50400.0%. This contributed to the annual value of 21.11% for FY2025, which is 50400.0% up from last year.
  • As of Q4 2025, Astrazeneca's EBT Margin stood at 16.96%, which was up 57700.0% from 21.35% recorded in Q3 2025.
  • Astrazeneca's 5-year EBT Margin high stood at 517.98% for Q3 2022, and its period low was 20.28% during Q3 2021.
  • In the last 5 years, Astrazeneca's EBT Margin had a median value of 18.41% in 2023 and averaged 72.19%.
  • Per our database at Business Quant, Astrazeneca's EBT Margin surged by 5382600bps in 2022 and then tumbled by -5036000bps in 2023.
  • Quarter analysis of 5 years shows Astrazeneca's EBT Margin stood at 5.3% in 2021, then soared by 9399bps to 492.41% in 2022, then tumbled by -98bps to 7.46% in 2023, then surged by 50bps to 11.19% in 2024, then surged by 52bps to 16.96% in 2025.
  • Its EBT Margin stands at 16.96% for Q4 2025, versus 21.35% for Q3 2025 and 21.63% for Q2 2025.